RxDoctor Payments Data

Americo Simonini, MD

Cardiovascular Disease · Los Angeles, CANPI 1639230766

Payments from drug & device makers

$59,180in general payments, 2019–2025

Across 237 payments — averaging $249.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lexicon Pharmaceuticals, Inc.$54K
  • Novartis$1K
  • Amgen$874
  • E.r. Squibb & Sons, L.L.C.$555
  • Kestra Medical Technology Services, Inc.$275
  • Kiniksa Pharmaceuticals International, PLC$269
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$3,7876%
  • Speaking & faculty fees$43,47073%
  • Travel & lodging$5,3459%
  • Food & beverage$6,57811%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,180 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$604,562
Medicare patients
241
Services billed
10,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArcalystRilonacept22$493,032
MounjaroTirzepatide104$100,917
EliquisApixaban80$66,779
EntrestoSacubitril/Valsartan48$58,084
Repatha SureclickEvolocumab52$56,418
InpefaSotagliflozin41$38,532
OzempicSemaglutide36$37,927
FarxigaDapagliflozin Propanediol24$30,352
Praluent PenAlirocumab20$18,254
EdarbiAzilsartan Medoxomil22$14,009
VascepaIcosapent Ethyl11$11,621
PaxlovidNirmatrelvir/Ritonavir14$2,859
Rosuvastatin Calcium99$2,172
Ezetimibe40$1,553
Amlodipine Besylate131$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kiniksa Pharmaceuticals International, PLCArcalyst$269$493,03222 claims
Lilly USA, LLCMounjaro$26$100,917104 claims
PfizerEliquis, Paxlovid$51$69,63894 claims
NovartisEntresto$1,248$58,08448 claims
Lexicon Pharmaceuticals, Inc.Inpefa$54,376$38,53241 claims
AstraZenecaFarxiga$79$30,35224 claims
Arbor Pharmaceuticals, Inc.Edarbi$15$14,00922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →